These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 32737446)
21. Which questionnaires should we use to evaluate quality of life in patients with chronic graft-vs-host disease? Perić Z; Desnica L; Duraković N; Ostojić A; Pulanić D; Serventi-Seiwerth R; Prenc E; Basak G; Vrhovac R; Pavletic SZ; Nemet D Croat Med J; 2016 Feb; 57(1):6-15. PubMed ID: 26935610 [TBL] [Abstract][Full Text] [Related]
22. Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. Takahashi T; Arora M; Okoev G; DeFor TE; Weisdorf DJ; MacMillan ML Transplant Cell Ther; 2021 Aug; 27(8):667.e1-667.e5. PubMed ID: 34077812 [TBL] [Abstract][Full Text] [Related]
23. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
24. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234 [TBL] [Abstract][Full Text] [Related]
25. Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Gooptu M; Kim HT; Howard A; Choi SW; Soiffer RJ; Antin JH; Ritz J; Cutler CS Biol Blood Marrow Transplant; 2019 Nov; 25(11):2143-2151. PubMed ID: 31271885 [TBL] [Abstract][Full Text] [Related]
26. [Effects of chemotherapy combined with donor lymphocyte infusion on chronic graft-versus-host disease and prognosis in minimal residual disease positive patients after allogeneic hematopoietic stem cell transplantation]. Shi YX; Zhang XH; Xu LP; Wang Y; Yan CH; Chen H; Chen YY; Liu KY; Huang XJ; Mo XD Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):713-719. PubMed ID: 31648470 [No Abstract] [Full Text] [Related]
27. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation. Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514 [TBL] [Abstract][Full Text] [Related]
28. Donor Type and Disease Risk Predict the Success of Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 613 Adult Hematopoietic Cell Transplantation Recipients Using a Modified Composite Endpoint. Solh M; Zhang X; Connor K; Brown S; Morris LE; Holland HK; Bashey A; Solomon SR Biol Blood Marrow Transplant; 2017 Dec; 23(12):2192-2198. PubMed ID: 28864140 [TBL] [Abstract][Full Text] [Related]
30. Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. Grube M; Holler E; Weber D; Holler B; Herr W; Wolff D Biol Blood Marrow Transplant; 2016 Oct; 22(10):1781-1791. PubMed ID: 27343720 [TBL] [Abstract][Full Text] [Related]
31. Symptoms, Cytokines, and Quality of Life in Patients Diagnosed with Chronic Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation. Lynch Kelly D; Lyon DE; Ameringer SA; Elswick RK Oncol Nurs Forum; 2015 May; 42(3):265-75. PubMed ID: 25901378 [TBL] [Abstract][Full Text] [Related]
32. Quality of life and recovery after graft-versus-host disease. Baker KS; Fraser CJ Best Pract Res Clin Haematol; 2008 Jun; 21(2):333-41. PubMed ID: 18503996 [TBL] [Abstract][Full Text] [Related]
34. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. Soejima T; Shiohara M; Ishida Y; Inoue M; Hayakawa A; Sato A; Kamibeppu K; Atsuta Y; Yamashita T Int J Hematol; 2021 Apr; 113(4):566-575. PubMed ID: 33386599 [TBL] [Abstract][Full Text] [Related]
37. Coping and Modifiable Psychosocial Factors are Associated with Mood and Quality of Life in Patients with Chronic Graft-versus-Host Disease. Jacobs JM; Fishman S; Sommer R; Sereno I; Fenech A; Jankowski AL; Traeger L; Greer JA; Vanderklish J; Hunnewell C; Saylor M; Chen YB; Spitzer T; DeFilipp Z; Temel JS; El-Jawahri A Biol Blood Marrow Transplant; 2019 Nov; 25(11):2234-2242. PubMed ID: 31260800 [TBL] [Abstract][Full Text] [Related]
38. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab. Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915 [TBL] [Abstract][Full Text] [Related]
39. Quality of Life following Allogeneic Stem Cell Transplantation for Patients Age >60 Years with Acute Myelogenous Leukemia. Wright R; Oremek M; Davies D; Kewley C; Singh A; Taitt N; Kempshall E; Wilson K; Ingram W Biol Blood Marrow Transplant; 2020 Aug; 26(8):1527-1533. PubMed ID: 32422252 [TBL] [Abstract][Full Text] [Related]